These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10419843)

  • 1. Pharmacokinetics and metabolism in early drug discovery.
    Smith DA; van de Waterbeemd H
    Curr Opin Chem Biol; 1999 Aug; 3(4):373-8. PubMed ID: 10419843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.
    Ito K; Kusuhara H; Sugiyama Y
    Pharm Res; 1999 Feb; 16(2):225-31. PubMed ID: 10100307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.
    van Waterschoot RA; Lagas JS; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2010 Dec; 127(12):2959-64. PubMed ID: 21351274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships of cyclotetrapeptides: interaction of tentoxin derivatives with three membrane proteins.
    Loiseau N; Delaforge M; Minoletti C; André F; Garrigues A; Orlowski S; Gomis JM
    Adv Exp Med Biol; 2001; 500():343-6. PubMed ID: 11764966
    [No Abstract]   [Full Text] [Related]  

  • 6. Modulation, absorption and delivery of xenobiotics: the synergic role of CYP450 and P-gp activities.
    Colabufo NA
    Curr Drug Metab; 2011 Oct; 12(8):701. PubMed ID: 22150749
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
    Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
    Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
    Patel J; Mitra AK
    Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grapefruit juice activates P-glycoprotein-mediated drug transport.
    Soldner A; Christians U; Susanto M; Wacher VJ; Silverman JA; Benet LZ
    Pharm Res; 1999 Apr; 16(4):478-85. PubMed ID: 10227700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carrier-mediated transport of macrolide antimicrobial agents across Caco-2 cell monolayers.
    Saito H; Fukasawa Y; Otsubo Y; Yamada K; Sezaki H; Yamashita S
    Pharm Res; 2000 Jun; 17(6):761-5. PubMed ID: 10955854
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin.
    Hong SP; Yang JS; Han JY; Ha SI; Chung JW; Koh YY; Chang KS; Choi DH
    J Pharm Pharmacol; 2011 Jan; 63(1):129-35. PubMed ID: 21189658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
    Cummins CL; Jacobsen W; Benet LZ
    J Pharmacol Exp Ther; 2002 Mar; 300(3):1036-45. PubMed ID: 11861813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man.
    Abel S; Beaumont KC; Crespi CL; Eve MD; Fox L; Hyland R; Jones BC; Muirhead GJ; Smith DA; Venn RF; Walker DK
    Xenobiotica; 2001; 31(8-9):665-76. PubMed ID: 11569532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
    Tachibana T; Kato M; Takano J; Sugiyama Y
    Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of the mechanisms of the drug-drug interaction from a view of pharmacogenomics].
    Sai Y; Tsuji A
    Nihon Rinsho; 2002 Jan; 60(1):74-80. PubMed ID: 11808342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico, in vitro and in situ models to assess interplay between CYP3A and P-gp.
    Mudra DR; Desino KE; Desai PV
    Curr Drug Metab; 2011 Oct; 12(8):750-73. PubMed ID: 21568936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic drug monitoring of immunosuppresants].
    Hashida T; Inui K
    Rinsho Byori; 2001 Jul; 49(7):662-4. PubMed ID: 11519126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
    Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
    Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin.
    Choi SJ; Shin SC; Choi JS
    Arch Pharm Res; 2011 Feb; 34(2):309-15. PubMed ID: 21380815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal function and morphology after ex vivo irradiated small bowel transplantation.
    Ishikawa T; Iwanami K; Okuda T; Zhu Y; Fukuda A; Zhang S; Ou J; Nalesnik MA; Venkataramanan R; Murase N
    Transplant Proc; 2002 May; 34(3):988-9. PubMed ID: 12034274
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.